Education
About Us
Working with TipRanks
Follow Us
InDex Pharmaceuticals Holding AB (DE:1NP1)
FRANKFURT:1NP1
Total Valuation
InDex Pharmaceuticals Holding AB has a market cap or net worth of €252.35M. The enterprise value is €2.13B.
Market Cap€252.35M
Enterprise Value€2.13B
Share Statistics
InDex Pharmaceuticals Holding AB has 77,455,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding77,455,960
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
InDex Pharmaceuticals Holding AB’s return on equity (ROE) is -0.22 and return on invested capital (ROIC) is 5828.87%.
Return on Equity (ROE)-0.22
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)5828.87%
Return on Capital Employed (ROCE)-0.23
Revenue Per Employee1.10M
Profits Per Employee-94.61M
Employee Count8
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of InDex Pharmaceuticals Holding AB is ―. InDex Pharmaceuticals Holding AB’s PEG ratio is -0.02.
PE Ratio―
PS Ratio331.74
PB Ratio0.86
Price to Fair Value0.86
Price to FCF0.00
Price to Operating Cash Flow-94.96
PEG Ratio-0.02
Income Statement
In the last 12 months, InDex Pharmaceuticals Holding AB had revenue of 8.80M and earned -756.90M in profits. Earnings per share was -9.71.
Revenue8.80M
Gross Profit-12.70M
Operating Income-782.10M
Pretax Income-757.90M
Net Income-756.90M
EBITDA-781.50M
Earnings Per Share (EPS)-9.71
Cash Flow
In the last 12 months, operating cash flow was -28.10M and capital expenditures 3.30M, giving a free cash flow of -24.80M billion.
Operating Cash Flow-28.10M
Free Cash Flow-24.80M
Free Cash Flow per Share-0.32
Dividends & Yields
InDex Pharmaceuticals Holding AB pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.27
52-Week Price Change-24.22%
50-Day Moving Average3.33
200-Day Moving Average3.64
Relative Strength Index (RSI)35.14
Average Volume (3m)0.00
Important Dates
InDex Pharmaceuticals Holding AB upcoming earnings date is Apr 15, 2026, TBA (Confirmed).
Last Earnings DateJan 21, 2026
Next Earnings DateApr 15, 2026
Ex-Dividend Date―
Financial Position
InDex Pharmaceuticals Holding AB as a current ratio of 0.00, with Debt / Equity ratio of 0.11%
Current Ratio0.00
Quick Ratio0.00
Debt to Market Cap<0.01
Net Debt to EBITDA0.69
Interest Coverage Ratio-57.09
Taxes
In the past 12 months, InDex Pharmaceuticals Holding AB has paid -1.00M in taxes.
Income Tax-1.00M
Effective Tax Rate<0.01
Enterprise Valuation
InDex Pharmaceuticals Holding AB EV to EBITDA ratio is -3.05, with an EV/FCF ratio of 0.00.
EV to Sales270.77
EV to EBITDA-3.05
EV to Free Cash Flow0.00
EV to Operating Cash Flow-84.80
Balance Sheet
InDex Pharmaceuticals Holding AB has €540.20M in cash and marketable securities with €3.70M in debt, giving a net cash position of €536.50M billion.
Cash & Marketable Securities€540.20M
Total Debt€3.70M
Net Cash€536.50M
Net Cash Per Share€6.93
Tangible Book Value Per Share€43.32
Margins
Gross margin is -133.68%, with operating margin of -8887.50%, and net profit margin of -8601.14%.
Gross Margin-133.68%
Operating Margin-8887.50%
Pretax Margin-8612.50%
Net Profit Margin-8601.14%
EBITDA Margin-8880.68%
EBIT Margin-8456.82%
Analyst Forecast
The average price target for InDex Pharmaceuticals Holding AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―